Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study

Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study

Purpose TFE3-rearranged/TFEB-altered renal cell carcinoma (RCC) is a rare subtype of RCC. Due to its rarity, there is an unmet medical need for effective therapies in advanced settings. The study aims to investigate the clinical and histopathological characteristics of patients with microphthalmia t...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Joohyun Hong, Ghee Young Kwon, Minyong Kang, Seong Il Seo, Se Hoon Park
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Korean Urological Oncology Society 2024-03-01
Saila:Journal of Urologic Oncology
Gaiak:
-rearranged
-altered
renal cell carcinoma
tyrosine kinase inhibitors
immune checkpoint inhibitors
Sarrera elektronikoa:http://www.e-juo.org/upload/pdf/juo-234600660033.pdf

Internet

http://www.e-juo.org/upload/pdf/juo-234600660033.pdf

Antzeko izenburuak